IDDF2024-ABS-0272 CircUGGT2 downregulation by METTL14-dependent m6a modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186- 3p/MAP3K9 axis

<h3>Background</h3> Chemoresistance is a major therapeutic challenge in advanced gastric cancer (GC). N6-methyladenosine (m6A) RNA modification has been shown to play fundamental roles in cancer progression. However, the underlying mechanisms by which m6A modification of circRNAs contributes to GC and chemoresistance remain unknown. <h3>Methods</h3> Through m6A-circRNA epitranscriptome microarray screening and RNA immunoprecipitation (RIP) analysis, we identified the influence of METTL14 on the m6A modification of circUGGT2 in cisplatin (DDP)-resistant GC cells, we analyzed its role in GC. Through <i>in vivo</i> and <i>in vitro</i> studies of the knockout and overexpression of circUGGT2, we investigated its effects on cell growth, migration, and DDP resistance. We further explored the relationship between circUGGT2 and miR-186-3p and its regulation of MAP3K9. Finally, we analyzed clinical data to assess the prognostic value of circUGGT2 in GC patients. <h3>Results</h3> We found that hsa_circ_0030632 (circUGGT2) was a predominant m6A target of METTL14, and METTL14 knockdown (KD) reduced circUGGT2 m6A levels but increased its mRNA levels. The expression of circUGGT2 was markedly increased in cisplatin (DDP)-resistant GC cells. CircUGGT2 KD impaired cell growth, metastasis and DDP-resistance <i>in vitro</i> and <i>in vivo</i>, but circUGGT2 overexpression prompted these effects. Furthermore, circUGGT2 was validated to sponge miR-186-3p and upregulate MAP3K9 and could abolish METTL14-caused miR-186-3p upregulation and MAP3K9 downregulation in GC cells. CircUGGT2 negatively correlated with miR-186-3p expression and harbored a poor prognosis in patients with GC (IDDF2024-ABS-0272 Figure1). <h3>Conclusions</h3> Our findings unveil that METTL14-dependent m6A modification of circUGGT2 inhibits GC progression and DDP-resistance by regulating miR-186-3p/MAP3K9 axis.

Authors

Institutions

Publication Details

Published
2024-08-01
DOI
https://doi.org/10.1136/gutjnl-2024-iddf.110
Primary Topic
RNA modifications and cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

IDDF2024-ABS-0272 CircUGGT2 downregulation by METTL14-dependent m6a modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186- 3p/MAP3K9 axis

Yi Yu, Jing Zhang, Xiaoyu Chen, Jinshui Zhu et al.
RNA modifications and cancer
article

IDDF2024-ABS-0272 CircUGGT2 downregulation by METTL14-dependent m6a modification suppresses gastric cancer progression and cisplatin resistance through interaction with miR-186- 3p/MAP3K9 axis

Yi Yu, Jing Zhang, Xiaoyu Chen, Jinshui Zhu, Yanling Yang, Zhaoyu Chen, Hui‐Ning Fan
article en

Abstract

<h3>Background</h3> Chemoresistance is a major therapeutic challenge in advanced gastric cancer (GC). N6-methyladenosine (m6A) RNA modification has been shown to play fundamental roles in cancer progression. However, the underlying mechanisms by which m6A modification of circRNAs contributes to GC and chemoresistance remain unknown. <h3>Methods</h3> Through m6A-circRNA epitranscriptome microarray screening and RNA immunoprecipitation (RIP) analysis, we identified the influence of METTL14 on the m6A modification of circUGGT2 in cisplatin (DDP)-resistant GC cells, we analyzed its role in GC. Through <i>in vivo</i> and <i>in vitro</i> studies of the knockout and overexpression of circUGGT2, we investigated its effects on cell growth, migration, and DDP resistance. We further explored the relationship between circUGGT2 and miR-186-3p and its regulation of MAP3K9. Finally, we analyzed clinical data to assess the prognostic value of circUGGT2 in GC patients. <h3>Results</h3> We found that hsa_circ_0030632 (circUGGT2) was a predominant m6A target of METTL14, and METTL14 knockdown (KD) reduced circUGGT2 m6A levels but increased its mRNA levels. The expression of circUGGT2 was markedly increased in cisplatin (DDP)-resistant GC cells. CircUGGT2 KD impaired cell growth, metastasis and DDP-resistance <i>in vitro</i> and <i>in vivo</i>, but circUGGT2 overexpression prompted these effects. Furthermore, circUGGT2 was validated to sponge miR-186-3p and upregulate MAP3K9 and could abolish METTL14-caused miR-186-3p upregulation and MAP3K9 downregulation in GC cells. CircUGGT2 negatively correlated with miR-186-3p expression and harbored a poor prognosis in patients with GC (IDDF2024-ABS-0272 Figure1). <h3>Conclusions</h3> Our findings unveil that METTL14-dependent m6A modification of circUGGT2 inhibits GC progression and DDP-resistance by regulating miR-186-3p/MAP3K9 axis.

Shanghai Jiao Tong University (CN), Shanghai Sixth People's Hospital (CN)
Good health and well-being
Openalex Percentile: Top 88%
RNA modifications and cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.